United States Air Force   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Washington DC United States (1907)

Organization Overview

First Clinical Trial
1997
NCT00413179
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

11 MDG | 375th Medical Group, Scott Air Force Base | Air Force | Air Force Research Laboratory | Air Force Specialized Hospital | David Grant Medical Center | David Grant U.S. Air Force Medical Center | Eglin AFB Hospital | Eglin AFB Regional Hospital | Eglin AFB, United States Air Force | Jennifer Loomis | Keesler Air Force Base Medical Center | Matthew Snyder | Mike O'Callaghan Federal Hospital | Mike O'Callaghan Federal Hospital/Nellis Air Force Base | Mike O'Callaghan Federal Medical Center | Mike O'Callaghan Military Hospital | Mike O'Callaghan Military Medical Center | Nellis AF | Seth Leavitt | Travis Callahan | United States Air Force | United States Air Force Research Laboratory | United States Air Force School of Aerospace Medicine | USAF David Grant Medical Center | US Air Force | U.S. Air Force Office of the Surgeon General | Wilford Hall Medical Center | Wilford Hall Medical Center, Lackland AFB, San Antonio, TX

Active Ingredients

Drugs in Phase 4 Trials (7)

allopurinol (zyloprim) (1 trial)

creatine (1 trial)

enoxaparin (lovenox) (1 trial)

inactivated influenza vaccine (2 trials)

ketamine (ketalar) (3 trials)

morphine (1 trial)

ursodeoxycholic acid (1 trial)

Drugs in Phase 3 Trials (14)

acetaminophen (tylenol) (1 trial)

cinnamon (3 trials)

clomifene (clomid) (1 trial)

gabapentin (neurontin) (1 trial)

hydrocortisone (solu-cortef) (1 trial)

ibuprofen (motrin) (2 trials)

methylsulfonylmethane (1 trial)

onabotulinumtoxinA (Botox) (1 trial)

oxycodone (oxycontin) (1 trial)

prochlorperazine (compazine) (1 trial)

sitagliptin (januvia) (2 trials)

thiamine (1 trial)

trimethoprim (3 trials)

vitamin c (1 trial)

Drugs in Phase 2 Trials (5)

bupivacaine (Exparel) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

lidocaine (xylocaine) (3 trials)

oxygen (1 trial)

sodium chloride (2 trials)

Drugs in Other Trials (23)

betamethasone (celestone) (1 trial)

caffeine (1 trial)

cinnulin (1 trial)

citalopram (celexa) (1 trial)

dipeptide alanyl-glutamine (1 trial)

diphenhydramine (benadryl) (1 trial)

epinephrine (levophed) (1 trial)

folic acid (1 trial)

iodine (1 trial)

lavender (1 trial)

methylprednisolone (medrol) (1 trial)

moxifloxacin (avelox) (1 trial)

ondansetron (zofran) (1 trial)

oryza sativa (1 trial)

pregabalin (lyrica) (1 trial)

red blood cells (1 trial)

rilonacept (arcalyst) (1 trial)

sertraline (zoloft) (1 trial)

sulfamethoxazole (gantanol) (1 trial)

tocilizumab (actemra) (1 trial)

topicaine (1 trial)

triamcinolone (kenalog) (1 trial)

water (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abdomen, Acute (Phase 4)

Abscess (Phase 3)

Acute Pain (Phase 4)

Anovulation (Phase 3)

Back Pain (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Chronic Pain (Phase 3)

Cicatrix (Phase 2)

Compartment Syndromes (Phase 3)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Dyspepsia (Phase 3)

Emergencies (Phase 4)

Flank Pain (Phase 4)

Fractures, Bone (Phase 2)

Gout (Phase 4)

Headache (Phase 3)

Hyperandrogenism (Phase 3)

Infertility (Phase 3)

Influenza, Human (Phase 4)

Low Back Pain (Phase 3)

Pain, Postoperative (Phase 3)

Polycystic Ovary Syndrome (Phase 3)

Rib Fractures (Phase 2)

Sepsis (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Syndrome (Phase 3)

Systemic Inflammatory Response Syndrome (Phase 3)

Thromboembolism (Phase 4)

Toxemia (Phase 3)

Venous Thromboembolism (Phase 4)

Wounds and Injuries (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 44
  • # of Trial APIs: 49